Edarbi and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Edarbi (azilsartan medoxomil), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Crestor, and have Crohn's disease.

The phase IV clinical study analyzes which people have Weakness when taking Edarbi. It is created by eHealthMe based on reports of 344 people who have side effects when taking Edarbi from the FDA, and is updated regularly.

What is Edarbi?

Edarbi has active ingredients of azilsartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 404 Edarbi users. Check the latest studies of Edarbi.

What is Weakness?

Weakness is found to be associated with 3,641 drugs and 6,611 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 10, 2026

344 people reported to have side effects when taking Edarbi.
Among them, 12 people (3.49%) have Weakness.

Among these 12 people:

How long have people been on Edarbi when they have Weakness? *

What is the gender of people who have Weakness when taking Edarbi? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Weakness when taking Edarbi? *

What are other drugs people take besides Edarbi? *

What are other side effects people have besides Weakness? *

Nausea (feeling of having an urge to vomit): 5 people, 41.67%
Stress And Anxiety: 3 people, 25.00%
Gastritis (inflammation of stomach): 2 people, 16.67%
Pain: 2 people, 16.67%
Dizziness: 2 people, 16.67%
Drug Ineffective: 2 people, 16.67%
Chills (felling of cold): 2 people, 16.67%
Nausea And Vomiting: 2 people, 16.67%
Haematochezia (passage of stools containing blood): 2 people, 16.67%
Constipation: 2 people, 16.67%

What are the existing conditions these people have? *

Muscle Aches (muscle pain): 2 people, 16.67%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 16.67%
High Blood Cholesterol: 2 people, 16.67%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 16.67%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 8.33%
Parkinson's Disease: 1 person, 8.33%
Ovarian Cancer (cancer of ovary): 1 person, 8.33%
Nausea (feeling of having an urge to vomit): 1 person, 8.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 8.33%
Multiple Myeloma (cancer of the plasma cells): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Edarbi and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Edarbi:

Edarbi (404 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Edarbi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,641 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,611 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on azilsartan medoxomil (the active ingredients of Edarbi) and Edarbi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.